Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions
MCRB Stock Forecast
Seres Therapeutics stock forecast is as follows: an average price target of $1.25 (represents a 25.10% upside from MCRB’s last price of $1.00) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
MCRB Price Target
The average price target for Seres Therapeutics (MCRB) is $1.25 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $1.25 to $1.25. This represents a potential 25.10% upside from MCRB's last price of $1.00.
MCRB Analyst Ratings
According to 4 Wall Street analysts, Seres Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MCRB stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Seres Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Keay Nakae | Chardan Capital | $1.25 | $0.85 | 46.52% | 25.10% |
The latest Seres Therapeutics stock forecast, released on Jun 07, 2024 by Keay Nakae from Chardan Capital, set a price target of $1.25, which represents a 46.52% increase from the stock price at the time of the forecast ($0.85), and a 25.10% increase from MCRB last price ($1.00).
Seres Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $1.25 |
| Last Closing Price | $1.00 | $1.00 | $1.00 |
| Upside/Downside | -100.00% | -100.00% | 25.10% |
In the current month, the average price target of Seres Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Seres Therapeutics's last price of $1.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 07, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| May 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 06, 2024 | Chardan Capital | Buy | Buy | Hold |
| Apr 28, 2023 | Chardan Capital | Buy | Buy | Hold |
| Sep 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 08, 2022 | Jefferies | - | Buy | Upgrade |
Seres Therapeutics's last stock rating was published by Cowen & Co. on Sep 12, 2024. The company gave MCRB a "Buy" rating, the same as its previous rate.
Seres Therapeutics Financial Forecast
Seres Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $64.00K | $310.00K | $126.47M | $-522.00K | $975.00K | $3.44M | $1.22M | $1.49M | $7.22M | $126.72M | $5.26M | $5.72M | $17.56M | $1.42M | $6.04M | $8.19M | $7.62M | $7.03M | $12.53M | $7.32M | $3.97M | $3.02M |
| Avg Forecast | - | - | - | - | $268.67K | $25.83M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $4.37M | $3.16M |
| High Forecast | - | - | - | - | $268.67K | $25.83M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $5.25M | $3.79M |
| Low Forecast | - | - | - | - | $268.67K | $25.83M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $3.50M | $2.53M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | -0.41% | 0.21% | 1.01% | -0.33% | 0.16% | 0.49% | 0.27% | 0.18% | 0.59% | 4.44% | 0.90% | 0.89% | 2.90% | 0.19% | 0.63% | 0.96% | 1.22% | 1.05% | 1.54% | 0.48% | 0.91% | 0.95% |
Seres Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $250.00K, with a low forecast of $250.00K, and a high forecast of $250.00K. MCRB's average Quarter revenue forecast represents a 290.63% increase compared to the company's last Quarter revenue of $64.00K (Dec 23).
Seres Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | $-39.96M | $-47.41M | $49.52M | $-67.83M | $-65.29M | $-56.53M | $-61.55M | $-54.14M | $-53.53M | $70.45M | $-46.17M | $-33.29M | $-15.98M | $-27.97M | $-18.30M | $-17.36M | $-16.98M | $-14.53M | $-9.37M | $-21.79M | $-25.98M | $-23.74M |
| Avg Forecast | - | - | - | - | $-223.64K | $-21.50M | $219.61K | $-208.10K | $129.02K | $-1.25M | $-104.61M | $-1.32M | $-4.99M | $-5.83M | $-3.78M | $-44.77M | $-10.20M | $-23.74M | $-4.87M | $-24.70M | $-5.04M | $-6.05M | $-7.94M | $-17.36M | $-5.20M | $-5.58M | $-6.77M | $-11.68M | $-28.37M | $-24.82M |
| High Forecast | - | - | - | - | $-223.64K | $-21.50M | $219.61K | $-208.10K | $129.02K | $-1.25M | $-104.61M | $-1.32M | $-4.99M | $-5.83M | $-3.78M | $-35.82M | $-10.20M | $-23.74M | $-4.87M | $-19.76M | $-5.04M | $-6.05M | $-7.94M | $-13.89M | $-5.20M | $-5.58M | $-6.77M | $-9.34M | $-22.70M | $-19.86M |
| Low Forecast | - | - | - | - | $-223.64K | $-21.50M | $219.61K | $-208.10K | $129.02K | $-1.25M | $-104.61M | $-1.32M | $-4.99M | $-5.83M | $-3.78M | $-53.73M | $-10.20M | $-23.74M | $-4.87M | $-29.64M | $-5.04M | $-6.05M | $-7.94M | $-20.84M | $-5.20M | $-5.58M | $-6.77M | $-14.01M | $-34.04M | $-29.79M |
| Surprise % | - | - | - | - | - | - | - | - | -309.74% | 38.08% | -0.47% | 51.50% | 13.08% | 9.70% | 16.28% | 1.21% | 5.25% | -2.97% | 9.47% | 1.35% | 3.17% | 4.62% | 2.30% | 1.00% | 3.27% | 2.61% | 1.39% | 1.87% | 0.92% | 0.96% |
1 analysts predict MCRB's average Quarter EBITDA for Sep 23 to be $-1.25M, with a high of $-1.25M and a low of $-1.25M. This is -102.51% lower than Seres Therapeutics's previous annual EBITDA (Jun 23) of $49.52M.
Seres Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
| Net Income | - | - | - | - | - | - | - | - | $-41.25M | $-47.85M | $46.55M | $-71.78M | $-69.28M | $-60.90M | $-66.14M | $-57.50M | $-44.92M | $68.22M | $-48.33M | $-35.47M | $-18.25M | $-30.28M | $-20.71M | $-19.88M | $-18.78M | $-16.41M | $-10.76M | $-24.33M | $-27.92M | $-25.47M |
| Avg Forecast | $-26.77M | $-26.77M | $-28.79M | $-30.30M | $-31.97M | $-11.30M | $-41.53M | $-51.77M | $-75.24M | $-75.97M | $80.98M | $-83.33M | $-68.94M | $202.75M | $-90.34M | $-46.82M | $-66.16M | $-8.25M | $-56.06M | $-26.31M | $-42.42M | $-38.74M | $-39.18M | $-19.88M | $-42.17M | $-48.70M | $-71.78M | $-13.04M | $-30.49M | $-26.63M |
| High Forecast | $-26.77M | $-26.77M | $-28.79M | $-30.30M | $-31.97M | $-10.82M | $-41.53M | $-51.77M | $-62.08M | $-75.97M | $80.98M | $-83.33M | $-68.94M | $243.30M | $-90.34M | $-37.46M | $-66.16M | $-8.25M | $-56.06M | $-21.05M | $-42.42M | $-38.74M | $-39.18M | $-15.90M | $-42.17M | $-48.70M | $-71.78M | $-10.43M | $-24.39M | $-21.31M |
| Low Forecast | $-26.77M | $-26.77M | $-28.79M | $-30.30M | $-31.97M | $-12.24M | $-41.53M | $-51.77M | $-92.17M | $-75.97M | $80.98M | $-83.33M | $-68.94M | $162.20M | $-90.34M | $-56.19M | $-66.16M | $-8.25M | $-56.06M | $-31.58M | $-42.42M | $-38.74M | $-39.18M | $-23.86M | $-42.17M | $-48.70M | $-71.78M | $-15.65M | $-36.59M | $-31.96M |
| Surprise % | - | - | - | - | - | - | - | - | 0.55% | 0.63% | 0.57% | 0.86% | 1.01% | -0.30% | 0.73% | 1.23% | 0.68% | -8.27% | 0.86% | 1.35% | 0.43% | 0.78% | 0.53% | 1.00% | 0.45% | 0.34% | 0.15% | 1.87% | 0.92% | 0.96% |
Seres Therapeutics's average Quarter net income forecast for Sep 23 is $-75.97M, with a range of $-75.97M to $-75.97M. MCRB's average Quarter net income forecast represents a -263.20% decrease compared to the company's last Quarter net income of $46.55M (Jun 23).
Seres Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
| SG&A | - | - | - | - | - | - | - | - | $13.18M | $19.99M | $28.05M | $22.47M | $22.40M | $18.38M | $20.34M | $18.57M | $20.51M | $19.56M | $17.45M | $11.74M | $10.60M | $7.55M | $6.49M | $6.14M | $5.78M | $5.90M | $5.57M | $7.50M | $8.78M | $8.76M |
| Avg Forecast | - | - | - | - | $752.09K | $72.32M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $6.14M | $17.48M | $18.75M | $22.75M | $4.02M | $12.24M | $8.84M |
| High Forecast | - | - | - | - | $752.09K | $72.32M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $7.37M | $17.48M | $18.75M | $22.75M | $4.82M | $14.69M | $10.61M |
| Low Forecast | - | - | - | - | $752.09K | $72.32M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $4.91M | $17.48M | $18.75M | $22.75M | $3.21M | $9.80M | $7.07M |
| Surprise % | - | - | - | - | - | - | - | - | -30.38% | 4.77% | 0.08% | 5.07% | 1.33% | 0.94% | 1.60% | 0.78% | 0.60% | 0.25% | 1.06% | 0.65% | 0.62% | 0.37% | 0.24% | 1.00% | 0.33% | 0.31% | 0.24% | 1.87% | 0.72% | 0.99% |
Seres Therapeutics's average Quarter SG&A projection for Mar 24 is $699.83K, based on 1 Wall Street analysts, with a range of $699.83K to $699.83K. The forecast indicates a -94.69% fall compared to MCRB last annual SG&A of $13.18M (Dec 23).
Seres Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
| EPS | - | - | - | - | - | - | - | - | $-0.32 | $-0.37 | - | $-0.57 | $-0.64 | $-0.50 | $-0.72 | $-0.62 | $-0.49 | $0.74 | $-0.53 | $-0.39 | $-0.22 | $-0.36 | $-0.28 | $-0.28 | $-0.27 | $-0.23 | $-0.24 | $-0.59 | $-0.69 | $-0.63 |
| Avg Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.21 | $-0.07 | $-0.27 | $-0.34 | $-0.50 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-0.83 | $-0.69 |
| High Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.21 | $-0.07 | $-0.27 | $-0.34 | $-0.41 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-0.66 | $-0.55 |
| Low Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.21 | $-0.08 | $-0.27 | $-0.34 | $-0.61 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-1.00 | $-0.83 |
| Surprise % | - | - | - | - | - | - | - | - | 0.64% | 0.74% | 0.00% | 1.04% | 1.41% | 1.07% | 1.21% | 1.18% | 1.12% | -13.59% | 1.43% | 1.26% | 0.78% | 1.41% | 1.08% | 1.00% | 0.95% | 0.72% | 0.51% | 1.49% | 0.83% | 0.91% |
According to 1 Wall Street analysts, Seres Therapeutics's projected average Quarter EPS for Sep 23 is $-0.50, with a low estimate of $-0.50 and a high estimate of $-0.50. This represents a -125457.50% decrease compared to MCRB previous annual EPS of - (Jun 23).
Seres Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NSTG | NanoString | $0.11 | $21.50 | 19445.45% | Buy |
| SYRS | Syros Pharmaceuticals | $1.95 | $19.33 | 891.28% | Buy |
| FATE | Fate Therapeutics | $4.02 | $39.75 | 888.81% | Buy |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
| VCYT | Veracyte | $32.92 | $26.00 | -21.02% | Buy |
MCRB Forecast FAQ
Is Seres Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Seres Therapeutics (MCRB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of MCRB's total ratings.
What is MCRB's price target?
Seres Therapeutics (MCRB) average price target is $1.25 with a range of $1.25 to $1.25, implying a 25.10% from its last price of $0.999. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Seres Therapeutics stock go up soon?
According to Wall Street analysts' prediction for MCRB stock, the company can go up by 25.10% (from the last price of $0.999 to the average price target of $1.25), up by 25.10% based on the highest stock price target, and up by 25.10% based on the lowest stock price target.
Can Seres Therapeutics stock reach $1?
MCRB's average twelve months analyst stock price target of $1.25 supports the claim that Seres Therapeutics can reach $1 in the near future.
What are Seres Therapeutics's analysts' financial forecasts?
Seres Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.09M (high $26.09M, low $26.09M), average EBITDA is $-21.716M (high $-21.716M, low $-21.716M), average net income is $-137M (high $-136M, low $-137M), average SG&A $73.03M (high $73.03M, low $73.03M), and average EPS is $-0.901 (high $-0.898, low $-0.907). MCRB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-113M (high $-113M, low $-113M), average SG&A $0 (high $0, low $0), and average EPS is $-0.743 (high $-0.743, low $-0.743).
Did the MCRB's actual financial results beat the analysts' financial forecasts?
Based on Seres Therapeutics's last annual report (Dec 2023), the company's revenue was $126.32M, which missed the average analysts forecast of $128.59M by -1.76%. Apple's EBITDA was $-108M, beating the average prediction of $-107M by 0.88%. The company's net income was $-114M, missing the average estimation of $-154M by -25.95%. Apple's SG&A was $87.74M, missing the average forecast of $359.98M by -75.63%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.014 by -99.91%. In terms of the last quarterly report (Dec 2023), Seres Therapeutics's revenue was $64K, missing the average analysts' forecast of $-155K by -141.29%. The company's EBITDA was $-39.963M, missing the average prediction of $129.02K by -31074.03%. Seres Therapeutics's net income was $-41.248M, missing the average estimation of $-75.244M by -45.18%. The company's SG&A was $13.18M, missing the average forecast of $-434K by -3137.82%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.497 by -35.56%